Floatz logo

FURAPREVIR

Cirrhosis

Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.Small moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
73/ 100

Competitive context

69 Active assets in the Cirrhosis cohort.

Asset / SponsorPhaseRating
GLY-GLY-GLY-CYS-TYR-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (4-9 DISULFIDE)
General Hospital of Shenyang Military Region
Phase 4BBB
Tolvaptan
Institute of Liver and Biliary Sciences, India
Phase 4BBB
NORMAL HUMAN SERUM ALBUMIN
King George's Medical University
Phase 4BBB
Ribavirin
Peking University People's Hospital
Phase 4BBB
CARVEDILOL
West China Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

FURAPREVIR is also rated in:

cirrhosis of liverDormant
BB
Indicative ·
69 / 100
View asset →
chronic hepatitis C virus infectionDormant
BB
Indicative ·
69 / 100
View asset →
Treatment naïveDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →